Regulus Therapeutics reported $-7175000 in Operating Profit for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Operating Profit Change
Alnylam Pharmaceuticals ALNY:US $ -191.69M 44.95M
AstraZeneca AZN:LN 44.27B 22.58B
Astrazeneca AZN:US 539M 339M
Biogen BIIB:US $ -59.1M 669.8M
Celldex Therapeutics CLDX:US $ -36.4M 13.14M
Gilead Sciences GILD:US $ 2029M 1832M
GlaxoSmithKline GSK:LN 108.1B 121.2B
Intercept Pharmaceuticals ICPT:US $ -13.36M 3.09M
Intrexon XON:US $ -24.16M 6.27M
Lexicon Pharmaceuticals LXRX:US -24007000 627K
Ligand Pharmaceuticals LGND:US $ -0.47M 7.34M
Merk MRK:US $ 4927M 642M
Omeros OMER:US $ -37438000 2.39M
Regulus Therapeutics RGLS:US $ -7.18M 0.61M
Sangamo Biosciences SGMO:US $ -45.73M 0.47M
Spectrum Pharmaceuticals SPPI:US $ -25.39M 11.33M
Takeda 4502:JP Y 150515M 152134M
Vital Therapies VTL:US $ -20.61M 0.82M
YTE INCY:US $ 254.43M 137.89M